EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone‐to‐renin ratio, an indicator of sodium retention, in healthy volunteers

Paolo Mulatero iD, Michael Groessl, Bruno Vogt, Christoph Schumacher, Ronald Edward Steele, Ashley Brooks iD, Stuart Hossack, Hans-Rudolf Brunner

British Journal of Clinical Pharmacology · 2023

DOI: 10.1111/bcp.15713 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Paolo Mulatero und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine and Hypertension, University of Torino, Torino, Italy. Hauptthemen laut MEDLINE: Aldosterone, Hypertension. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

High aldosterone is a key driver of hypertension and long‐term negative sequelae. We evaluated the safety and efficacy of dexfadrostat phosphate (DP13), a novel aldosterone synthase (CYP11B2) inhibitor, in healthy participants.

Methods

This randomized, double‐blind, placebo‐controlled study was conducted in two parts. In part A, a single‐ascending dose escalation, 16 participants received oral DP13 1–16 mg. Part B was a multiple‐ascending dose, sequential group study in which 32 participants received oral DP13 4, 8 or 16 mg once daily for 8 days. Safety and tolerability were monitored throughout. An adrenocorticotropic hormone (ACTH) stimulation test at maximal blood drug concentrations defined the dose range for multiple dosing.

Results

DP13 was well tolerated at all doses, with no serious adverse events. In part B, all DP13 doses (4, 8 and 16 mg) over 8 days effectively suppressed aldosterone production, increased the urinary sodium/potassium ratio, decreased plasma sodium and increased plasma potassium and renin levels compared with placebo, resulting in potent suppression of the aldosterone‐to‐renin ratio (ARR). Endocrine counter‐regulation resulted in the 4 mg dose no longer sustaining 24‐h aldosterone suppression after 8 days of treatment, unlike the 8‐ and 16 mg doses. There was no evidence of drug‐induced adrenal insufficiency (ACTH stress challenge).

Conclusions

In patients with excess aldosterone and ensuing sodium retention driving hypertension, managing sodium balance is critical. A CYP11B2 inhibitor like DP13, whose effectiveness can be monitored by a reduction in ARR, may prove valuable in managing aldosterone‐dependent hypertension and primary aldosteronism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AldosteroneHypertensionHumansReninCytochrome P-450 CYP11B2Healthy VolunteersPhosphatesSodiumAdrenocorticotropic HormonePotassium

Stichwörter der Autor:innen

CYP11B2aldosteronealdosterone synthase inhibitionaldosterone-to-renin ratiohealthy volunteersreninsodium/potassium balance

Substanzen

AldosteroneReninCytochrome P-450 CYP11B2PhosphatesSodiumAdrenocorticotropic HormonePotassium

Autor:innen und Institutionen

  • Division of Internal Medicine and Hypertension, University of Torino, Torino, Italy.
  • Clinic for Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • DAMIAN Pharma AG, Walchwil, Switzerland.
  • Covance Clinical Research, Leeds, UK.
  • Faculty of Biology and Medicine, Lausanne University, Lausanne, Switzerland.

ORCID-Profile: Paolo Mulatero, Ashley Brooks

Zitieren

APA

Mulatero, P., Groessl, M., Vogt, B., Schumacher, C., Steele, R. E., Brooks, A., Hossack, S., & Brunner, H. R. (2023). CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone‐to‐renin ratio, an indicator of sodium retention, in healthy volunteers. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15713

Vancouver

Mulatero P, Groessl M, Vogt B, Schumacher C, Steele RE, Brooks A, et al. CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone‐to‐renin ratio, an indicator of sodium retention, in healthy volunteers. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15713

BibTeX
@article{Mulatero2023,
  author = {Mulatero, Paolo and Groessl, Michael and Vogt, Bruno and Schumacher, Christoph and Steele, Ronald Edward and Brooks, Ashley and Hossack, Stuart and Brunner, Hans-Rudolf},
  title = {CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone‐to‐renin ratio, an indicator of sodium retention, in healthy volunteers},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1111/bcp.15713}
}
Kostenlos starten →